Nothing newsworthy is happening on the Copaxone program, which is in litigation with Teva.
Craig Wheeler had said one could follow whats going on by looking at the various legal filings. I am not sure where to look but on seeing the price movement today one thing I suspected was perhaps something in there looks favorable to Momenta.
MNTA: Perhaps the group think is that the FDA has already decided on an approval, yet, chose to wait until 01 Apr to avoid issuing a tentative approval. We all know the exclusivity clock expires at that time. Other than that, it could be your old "regression to the mean argument" in front of an imminent decision.
Market Data 
Markets 
AI
